Psoriatic Arthritis Carries a Modest Mortality Excess in Sweden, Then Comorbidity Explains It Away
A nationwide Swedish cohort study found psoriatic arthritis was associated with a modest increase in all-cause mortality compared with the general population, but the excess largely disappeared after comorbidity adjustment. The pattern was most visible in women and in patients living longer with the disease, a signal that points less to psoriatic arthritis alone and more to the cumulative burden of systemic illness that often travels with it.
The design was broad and population-based, drawing adults with at least one main PsA diagnosis from outpatient rheumatology and internal medicine departments between 2001 and 2017 through the Swedish National Patient Register. Each patient was matched to five population comparators on sex, county, and age at the first arthritis diagnosis, and follow-up began on 1 January 2007 or at first PsA diagnosis thereafter, continuing until death, emigration, or 31 December 2018. That structure allowed investigators to compare mortality over a long observation window while also examining how risk shifted by sex, age, and duration since diagnosis.
The main message was straightforward. All-cause mortality was elevated in PsA, with a hazard ratio of 1.11 and an incidence rate ratio of 1.18. In a disease long recognized for inflammatory burden beyond the joints, even a modest mortality difference matters because it reflects the combined effect of chronic inflammation, cardiometabolic disease, and the medical complexity that builds over years of follow-up. But the signal did not remain after accounting for comorbidity, suggesting that the mortality gap was driven largely by the illnesses that cluster around PsA rather than by PsA diagnosis alone.
Women and Longer Disease Duration Carried the Strongest Mortality Signal
Sex-stratified analyses showed the clearest excess in women, who had a hazard ratio of 1.23 for death compared with matched comparators. Patients with longer time since diagnosis also had higher mortality, with a hazard ratio of 1.18 in that subgroup. Those two findings fit the biology and the clinical course of PsA. Chronic inflammatory disease does not remain confined to the musculoskeletal system; over time it often coexists with hypertension, diabetes, obesity, and cardiovascular disease, all of which can deepen risk as exposure lengthens. The prolonged-disease signal is especially important because it suggests a cumulative burden rather than an early, abrupt mortality hazard.
A single sentence captures the central tension in the data: the mortality difference was real, but it was not autonomous.
Age-stratified incidence rate ratios also showed increased death rates across all ages except below 40 years, with the highest point estimates in the 40 to 59 year range. That middle-age pattern is clinically plausible. Patients in that age band are often old enough for cumulative inflammatory and metabolic damage to have accumulated, yet young enough that a relative increase in death rate can be especially meaningful over the course of decades. The lack of increased risk below age 40 suggests that the mortality burden emerges after enough time has passed for comorbidity to consolidate.
Cardiovascular Disease and Malignancy Dominated Causes of Death
Causes of death were similar in PsA cases and comparators, and cardiovascular disease and malignancy were the leading causes in both groups. That finding is important because it frames mortality in PsA as part of the broader chronic disease spectrum rather than as a unique fatal complication of arthritis itself. PsA is a systemic inflammatory disease, and systemic inflammation is biologically linked to atherosclerosis, endothelial dysfunction, and plaque instability. At the same time, the matching of causes of death suggests that the excess risk is not being driven by an unusual terminal phenotype; it is more likely the result of a higher prevalence of the same major causes that affect the general population, amplified by comorbidity.
The study also examined incidence rate ratios for death overall and by sex, duration since diagnosis, and age. Those analyses reinforced the same theme: the unadjusted or minimally adjusted mortality excess was measurable, but the comorbidity-adjusted association was not. In practical terms, the mortality gap appears to be mediated through the burden of associated disease rather than through PsA alone. For clinicians, that shifts attention toward aggressive cardiovascular risk assessment, malignancy vigilance where appropriate, and careful management of the non-rheumatologic illnesses that so often accompany chronic inflammatory arthritis.
What the Swedish Cohort Says About Bedside Risk
The study adds a population-level perspective that is difficult to obtain from smaller clinic cohorts. Because the data came from a nationwide registry and included long follow-up, the analysis captures real-world disease burden rather than a narrow trial population. It also reflects routine care across outpatient rheumatology and internal medicine settings, where comorbidity is common and where mortality risk is shaped by a patient’s full medical history, not just joint inflammation.
For bedside practice, the findings argue against viewing PsA mortality as an isolated rheumatologic endpoint. The excess risk was modest, and once comorbidity entered the model, the association disappeared. In other words, the patient with PsA who is most likely to die earlier is often the patient carrying cardiovascular disease, metabolic disease, or other systemic illness alongside arthritis. The sex difference, with higher risk in women, deserves attention as well, because it suggests that risk assessment should not be calibrated only around the average patient profile.
The data also reinforce the importance of disease duration. Patients living longer with PsA may accumulate injury from inflammation and from the conditions that develop around it, making long-term surveillance essential. Cardiovascular disease remained one of the leading causes of death, which keeps prevention in sharp focus: blood pressure, lipids, glycemic status, body weight, smoking history, and overall inflammatory control all sit inside the same risk equation.
This study does not show that PsA independently drives mortality once comorbidity is accounted for, and it does not identify a specific treatment exposure responsible for the observed pattern. What it does show is that mortality in PsA is real enough to measure and structured enough to dissect. The remaining challenge is not whether the signal exists, but how much of it can be prevented by earlier recognition of comorbidity, tighter cardiovascular prevention, and long-term follow-up of patients whose arthritis has already lasted for years.